Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$98.82 USD

98.82
666,765

+1.62 (1.67%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Reasons to Add Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

What's in Store for Abbott Laboratories (ABT) in Q3 Earnings?

by Zacks Equity Research

Abbott Laboratories' (ABT) third-quarter 2023 results are likely to reflect solid underlying base business organic sales growth.

HealthEquity (HQY) Up 4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on business recovery and expansion in emerging markets.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Medtronic (MDT) on strong global expansion.

Here's Why You Should Invest in Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN), driven by growth in vascular and neuro businesses.

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL), led by its digital transformation strategy.

Here's Why Investors Should Invest in Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on strong growth in the Diagnostics business and upbeat guidance.

QIAGEN (QGEN) Extends QIAwave Product Line With New Kit

by Zacks Equity Research

QIAGEN's (QGEN) new QIAwave kits broaden its selection of environmentally friendly products and reaffirm its commitment to helping researchers advance science.

Reasons to Retain Patterson Companies (PDCO) in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

HealthEquity (HQY) to Add Conduent's HSA Accounts in 2024

by Zacks Equity Research

HealthEquity (HQY) is set to receive the Conduent's HSA portfolio as a part of an agreement signed by the companies earlier this month. The deal is likely to boost HQY's business in 2024 and beyond.

3 Reasons to Hold HealthEquity (HQY) Stock in Your Portfolio

by Zacks Equity Research

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Abbott (ABT) Closes Acquisition Deal of Bigfoot Biomedical

by Zacks Equity Research

Abbott's (ABT) footprint in the diabetes care market is increased by the Bigfoot Biomedical acquisition.

Hologic (HOLX) to Boost Breast Imaging Modality With New Pact

by Zacks Equity Research

Hologic's (HOLX) collaboration with Bayer will enable physicians everywhere to include CEM in their breast cancer diagnosis workflows.

3 Reasons to Hold Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?

by Zacks Equity Research

Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and HealthEquity (HQY) have performed compared to their sector so far this year.

McKesson (MCK) Announces Availability of FDA-Cleared Drug for MF

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MF.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Walgreens (WBA) New Study Shows Medical Adherence Importance

by Zacks Equity Research

Walgreens' (WBA) latest research findings highlight the importance of patients adhering to their therapy.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX), backed by collaborations with health plans and upbeat guidance.

3 Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Bruker (BRKR) Advances Novel 4D-Proteomics Capabilities

by Zacks Equity Research

Bruker's (BRKR) commitment to innovation and customer support makes it a great partner and helps achieve its mission of translating nature into medicine.

Here's Why You Should Hold on to IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) on solid premium instrument placements and upbeat guidance.

Here's Why You Should Hold BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.